Maria Donniacuo
Overview
Explore the profile of Maria Donniacuo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
495
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Telesca M, De Angelis A, Donniacuo M, Bellocchio G, Riemma M, Mele E, et al.
Eur J Pharmacol
. 2024 Jul;
978:176794.
PMID: 38968980
Heart failure (HF) remains a huge medical burden worldwide, with aging representing a major risk factor. Here, we report the effects of sacubitril/valsartan, an approved drug for HF with reduced...
2.
Riemma M, Mele E, Donniacuo M, Telesca M, Bellocchio G, Castaldo G, et al.
Front Pharmacol
. 2024 Jul;
15:1422740.
PMID: 38948473
Heart failure and cognitive impairment emerge as public health problems that need to be addressed due to the aging global population. The conditions that often coexist are strongly related to...
3.
Rinaldi B, Cuzzocrea S, Donniacuo M, Capuano A, Di Palma D, Imperatore F, et al.
Intensive Care Med
. 2024 Feb;
50(3):491.
PMID: 38353715
No abstract available.
4.
Telesca M, Donniacuo M, Bellocchio G, Riemma M, Mele E, DellAversana C, et al.
Cancers (Basel)
. 2024 Jan;
16(1).
PMID: 38201480
The application of doxorubicin (DOX) is hampered by cardiotoxicity, with diastolic dysfunction as the earliest manifestation. Fibrosis leads to impaired relaxation, but the mechanisms that operate shortly after DOX exposure...
5.
Fusco A, Savio V, Perfetto B, Donniacuo M, Shadrina E, Donnarumma G, et al.
Lasers Med Sci
. 2023 Dec;
39(1):7.
PMID: 38097851
In recent years, some treatments for esthetic and pathologic skin conditions have increasingly been based on the use of non-ablative neodymium-doped yttrium aluminum garnet (Nd:YAG) laser due to its greater...
6.
Mascolo A, Rafaniello C, Mauro G, Ruggiero D, Campitiello M, Donniacuo M, et al.
Front Pharmacol
. 2023 Nov;
14:1245642.
PMID: 38027019
The risk of falls and bone fractures with sodium-glucose co-transporter-2 (SGLT2) inhibitors has been characterized by conflicting evidence. Therefore, we decided to investigate the reporting probability of falls and fractures...
7.
Ruggiero R, Donniacuo M, Mascolo A, Gaio M, Cappetta D, Rafaniello C, et al.
Biomedicines
. 2023 Jun;
11(6).
PMID: 37371680
Atrial fibrillation (AF) has been described in COVID-19 patients. Recently, some case reports and US pharmacovigilance analyses described AF onset as a rare adverse event following COVID-19 vaccination. The possible...
8.
Mascolo A, Sportiello L, Rafaniello C, Donniacuo M, Ruggiero D, Scisciola L, et al.
Biomed Pharmacother
. 2023 May;
164:114912.
PMID: 37210896
Background: Despite the available evidence showing an association between cardiac arrhythmia and Immune Checkpoint Inhibitors (ICIs), few studies have compared this risk between ICIs. Objectives: We aim to evaluate Individual...
9.
Pieretti G, Rafaniello C, Fraenza F, Donniacuo M, Cuomo R, Lanzano G, et al.
J Cosmet Dermatol
. 2023 May;
22(9):2420-2423.
PMID: 37128806
The use of hyaluronic acid (HA)-based aesthetic therapies is growing steadily, and according to the International Society of Aesthetic Plastic Surgery, more than 4.3 million aesthetic procedures using HA were...
10.
Ruggiero R, Balzano N, Di Napoli R, Fraenza F, Pentella C, Riccardi C, et al.
Front Immunol
. 2023 Apr;
14:1134436.
PMID: 37006303
Although the immunotherapy advent has revolutionized cancer treatment, it, unfortunately, does not spare cancer patients from possible immune-related adverse events (irAEs), which can also involve the peripheral nervous system. Immune...